Price
No data yet.
Social Signal Score
Revenue
$200.58M+225.17%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Timothy Herbert
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 1,333
- Beta
- 0.67
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 12.32
Financials
Revenue
$200.58M+225.2%Net Income
$314.0KEBITDA
$4.08MFree Cash Flow
$14.07MEPS (diluted)
$0.01Shares Outstanding (diluted)
28.94M+6.0%Operating Expenses
$171.97MCash & Debt
$320.68MReturn of Capital
$0.00Revenue by Segment (annual)
$911.98MDividend per Share
$9.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $911.98M | $145.42M | $4.95 |
| 2024 | $802.80M | $53.51M | $1.80 |
| 2023 | $624.80M | $-21.15M | $-0.72 |
| 2022 | $407.86M | $-44.88M | $-1.60 |
| 2021 | $233.39M | $-42.04M | $-1.54 |
| 2020 | $115.38M | $-57.20M | $-2.19 |
| 2019 | $82.05M | $-33.24M | $-1.40 |
| 2018 | $50.59M | $-21.83M | $-1.50 |
| 2017 | $28.57M | $-17.51M | $-1.30 |
| 2016 | $16.43M | $-18.53M | $-1.49 |
| 2015 | $8.01M | $-21.34M | $-1.71 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $7.28
- Implied price
- $138.23
- Return from $60.55
- 18.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $68.73 — today's price is already 11.9% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 13 | 16 | 19 | 22 | 25 |
|---|---|---|---|---|---|
| -2.0% | -0.8% | 3.4% | 7.0% | 10.2% | 13.1% |
| 3.0% | 4.3% | 8.7% | 12.5% | 15.8% | 18.8% |
| 8.0% | 9.3% | 14.0% | 18.0% | 21.5% | 24.6% |
| 13.0% | 14.4% | 19.2% | 23.4% | 27.1% | 30.4% |
| 18.0% | 19.5% | 24.5% | 28.9% | 32.7% | 36.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newszacks.com·5h ago·Neutral
Here's Why You Should Add INSP Stock to Your Portfolio Now Inspire Medical's Inspire V adoption, clinical evidence and underpenetrated OSA market support growth despite coding and reimbursement headwinds.
View source ↗
Earnings
Mon, Nov 2(in 2 months)
Consensus estimate $0.11 per share
Typical surprise +139.1% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$0.14 vs $-0.24beat
- Mon, May 4$0.10 vs $-0.28beat
- Wed, Feb 11$1.65 vs $0.69beat
- Mon, Nov 3$0.38 vs $-0.15beat
- Mon, Aug 4$0.45 vs $0.22beat
- Mon, May 5$0.10 vs $-0.23beat
Estimates and results for INSP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INSP officers and directors.
- Bought
- $804
- Sold
- $2.0m
2 trades
12 trades
- Kelly Jason Psold
- Rondoni Johnsold
- Rondoni Johnsold
- Mccormick Shawnsold
- Rondoni Johnsold
- Mccormick Shawnsold
- Mccormick Shawnsold
- Buchholz Richardsold
86 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.